Inhaled steroids improve pulmonary function and bronchial responsiveness in older asthmatics. Data from studies using subjective outcome measures to determine the effectiveness of inhaled steroids in infants with recurrent wheezing are equivocal. Therefore, this study tested the hypothesis that beclomethasone dipropionate improves pulmonary function, including bronchial responsiveness to histamine, in recurrently wheezy infants.
infants.
The study was double blind, placebo controlled lasting nine weeks. After the first baseline week, pulmonary function was measured using the rapid thoracoabdominal compression technique and bronchial responsiveness assessed with a histamine challenge test. Infants were then randomly allocated to receive doses of placebo or beclomethasone dipropionate (100 jig/puff) from metered aerosols. Two puffs of test aerosol were administered twice daily for eight weeks via a large volume spacer fitted with a facemask. Symptoms were recorded daily and pulmonary function and bronchial responsiveness assessed at the end of the treatment period; 50 infants, median age 12 months (range 5 to 18 months), were recruited. Twenty three in the beclomethasone dipropionate group and 15 in the placebo group completed the study and had pairs of pulmonary function measurements. Three were probable treatment failures (one beclomethasone dipropionate, two placebo), three were possible treatment failures (placebo), and others were non-compliant with study protocol. Baseline variables were not significantly different between those infants who completed the study and those who did not. Beclomethasone dipropionate and placebo groups were similar in all respects at baseline. Lung function and symptoms improved for both groups of infants during the study. Bronchial responsiveness increased significantly in the placebo group but there were no statistically significant differences between groups for any of the other outcome measures. It is concluded that beclomethasone dipropionate (400 ,ug daily) via a large volume More recent studies suggest that inhaled steroids might be effective in infants with wheezing. Inhaled beclomethasone dipropionate reduces wheezing after bronchiolitis6 7 and others report improvements in symptoms for wheezy children under 18 months8 and 3 years9 10 treated with inhaled budesonide. However, in a study of infants under 18 months of age with recurrent wheeze Van Bever et al failed to show a significant effect of aerosolised budesonide. I l All of these studies used subjective symptom scores as a primary outcome measure and none used objective measures of lung function.
We have recently demonstrated using the rapid thoracoabdominal compression technique that wheezy infants have reduced lung function compared with normal controls.'2 The aim of the present study was therefore to determine whether regular treatment with inhaled beclomethasone dipropionate improves lung function in wheezy infants. Because inhaled steroids improve non-specific bronchial responsiveness in older asthmatics we also determined the effect of treatment with beclomethasone dipropionate on bronchial responsiveness to histamine. '3 Subjects and methods
SUBJECTS
Fifty infants were enrolled into the trial. Criteria for entry were age less than 18 months and a history of three discrete episodes of wheezing or persistent wheezing for more than four weeks. Infants were excluded if they had an upper respiratory tract infection in the two weeks before the start of the study, if they had significant lung disease other than asthma, or if they were already receiving treatment with corticosteroids (oral or inhaled). Subjects were deemed as treatment failures if they were prescribed any asthma medication in addition to that being used before the start of the study, other than bronchodilators.
PROTOCOL
The study was a randomised, double blind, placebo controlled design lasting nine weeks. Infants attended the respiratory laboratory at Princess Margaret Hospital for Children on four occasions. During the first visit details of the subject's previous medical history were obtained and physical examination performed. The parents were issued with a simple diary to record daytime and nocturnal symptoms of cough and wheeze on a scale from 0 (no symptoms) to 3 (severe symptoms) and the use of medications for the duration of the study. The maximum possible daily symptom score was 12 indicating severe daytime and night time symptoms. A modified American Thoracic Society questionnaire was administered to determine the smoking habits and presence of atopy in primary relatives.
The first week of the study was used to establish the baseline symptom score. At the second visit each infant had lung function and response to inhaled histamine measured. Each child was then provided with a numbered metered aerosol inhaler corresponding to their study number containing beclomethasone dipropionate ( Baseline VmaxFRC was established as the mean of five forced expirations after the saline nebulisation. The bronchial challenge was performed using doubling concentrations of histamine from 0-125 g/l to a maximum concentration of 8 g/1.15 Doses were delivered every five minutes and respiratory function was assessed after each dose with a minimum of five forced expirations being performed. The challenge ceased when a response was recorded or the maximum concentration of histamine was reached. A response was defined as a fall in mean VmaxFRC of 40% or more from baseline and the provocation concentration for a fall inVmaxFRC (PC40) was derived from the plot of log concentration of histamine against VmaxFRC by linear interpolation between the last two points on the semilogarithmic dose response graph.
Written, informed consent was obtained from the parents of all subjects and the study was approved by the hospital's ethics committee.
STATISTICAL ANALYSIS
Lung function is expressed as raw VmaXFRC values and as % predictedVmaxFRc based on length.'6 Changes in lung function and PC40
were compared between groups using unpaired Student's t tests. Other data were compared using Student's unpaired t tests for normally distributed data and Mann-Whitney U tests for non-normally distributed data. Symptom scores are expressed as the mean score per week and were compared using analysis of variance for repeated measures.
Treatment failure was defined as 'probable' if additional asthma treatment was required after two weeks or more of treatment with test aerosol or 'possible' if additional treatment was required after less than two weeks' treatment.
Results
All 50 infants had baseline lung function measured. Twenty three infants in the beclomethasone dipropionate group and 15 in the placebo group completed the eight week treatment period and had pulmonary function measurements repeated. Twenty three infants (13 beclomethasone dipropionate, 10 placebo) completed two histamine challenges and 31 (20 beclomethasone dipropionate, 11 placebo) infants had complete diary records.
The ages, lengths, gender distribution, lung function, histamine responsiveness, and symptom scores at baseline for the initial 50 infants and those 38 in the final analysis were similar in the beclomethasone dipropionate and control groups (table 1) . The median duration of symptoms before the study was seven months (range 1 to 16 months) and was similar in each group.
There were no significant differences within the initial and final groups regarding a primary family history of asthma or smoke exposure. Seventy eight per cent of the beclomethasone dipropionate group had a family history of asthma compared with 81% of the placebo group; 57% of infants in the beclomethasone dipropionate group were exposed to environmental tobacco smoke at home compared with 75% of the placebo group.
Three infants from the placebo group and one from the beclomethasone dipropionate group were withdrawn from the study because (fig 3) . Furthermore, the mean proportion of symptom-free days in the beclomethasone dipropionate group (31%) was similar to that in the placebo group (37%). There were no specific guidelines given to the parents regarding use of bronchodilators but their use was similar in both groups and tended to decline during the study. The responses to beclomethasone dipropionate compared with placebo were no different in those infants with a family history of asthma or smoking.
Discussion
As far as we are aware this is the first study to evaluate the effect of inhaled steroids on objective measures of lung function in recurrently wheezy infants. Infants treated with beclomethasone dipropionate inhaled through a facemask from a large volume spacer did not have a significant improvement in lung function compared with infants treated with placebo. Despite overall improvements in lung function for infants in both treatment groups there was still evidence of significant airway obstruction at the end of the study with mean % predicted values for VmaxFRc of 57% in both the beclomethasone dipropionate and placebo groups. This suggests that if reversible airways narrowing was the cause of the low values of VmaxFRc there was still potential for substantial improvement.
Although infants in the placebo group had a significant increase in bronchial responsiveness during the study period compared with those who received beclomethasone dipropionate this may not be clinically relevant. A previous study suggests that increased bronchial responsiveness is not an important pathophysiological mechanism in infants with recurrent wheezing.12 Furthermore, in the present study increases in the level of bronchial responsiveness were not associated with worsening of lung function or symptom scores.
As with lung function, symptoms improved in both the beclomethasone dipropionate and There are a number of theoretical explanations related to methodology for the lack of response in 'VmaxFRc to beclomethasone dipropionate in our study.
(1) Inadequate dose: the actuated dose that we used is effective in older children and adults with asthma and is considerably larger than that used routinely in adults when considered in relation to body (and hence lung) size.17 (2) to be large enough to be clinically relevant. In fact, assuming a bayesian prior density that is uniform on the principal scale of analysis, it may be estimated2l that the posterior probability that the true difference between groups with respect to changes in % predicted VmaxFRc (beclomethasone dipropionate minus placebo) is as large as, or larger than, +40% (rather than -10-5% as observed) is less than 10-6 and the posterior probability that beclomethasone dipropionate offers any advantage at all (difference in change >0%) is only 10%. On the other hand, the study not only suggests that the change in PC40 differs significantly between the two treatment groups, but also suggests that there is a reasonably high posterior probability (71%) that the true difference is of a magnitude in excess of two doubling doses.
(4) Differential drop out: because of the design of the study, it was impossible to carry out an analysis based upon 'intention to treat'.
However, although this is unfortunate, it is unlikely that this would have led to a qualitative change in our principal inferences. With respect to the change in % predicted VmaxFRc, given that the placebo group exhibited a markedly (although non-significantly) more beneficial change than the beclomethasone dipropionate group, it would have to be postulated that there were either extreme negative changes in the placebo drop outs or extreme positive changes in the beclomethasone dipropionate drop outs in order to conceal an important real benefit of beclomethasone dipropionate. Given that there were no important baseline differences between the drop outs and those infants that completed the study, it would seem very unlikely that any putative changes in the drop outs would be large enough and sufficiently discordant with the changes in those who did not drop outs to support such a hypothesis. Similarly, large discordancies in the change in PC40 in drop outs would have to be postulated in order to support the hypothesis that there was really no difference between the two groups and that the apparent beneficial effect of beclomethasone dipropionate arose solely as a consequence of the differential non-response.
(5) Inadequate duration of treatment:
objective data from adults with asthma that includes assessments of pulmonary function and bronchial responsiveness suggest a plateau in the response to inhaled steroids at approximately eight weeks.13 Other studies in wheezy young children have reported functional improvement after shorter periods of treatment than in our study.6 8 Therefore, assuming that the low forced expiratory flows observed in recurrently wheezy infants result from similar pathophysiological mechanisms to those in older children and adults with asthma, the duration of treatment in our study should have been sufficient to demonstrate a beneficial effect of beclomethasone dipropionate on pulmonary function. However, recent studies suggest that the pathophysiological mechanisms responsible for recurrent wheezing in infants may be different from those involved in asthma later in life. The natural history of recurrent wheezing in the majority of infants is to resolve by school age2223 and there-is evidence that the airways of some infants are relatively small,'2 24 which might predispose them to wheezing when inflammation or oedema occurs secondary to some environmental trigger. Previous studies have suggested that treatment with inhaled steroids reduces the frequency of wheezing episodes after bronchiolitis.6 I Therefore, although beclomethasone dipropionate does not result in overall improvement in lung function or symptoms in the short term, it might be useful for reducing the frequency of wheezy episodes resulting from triggers such as viral respiratory infections and exposure to cigarette smoke, when treatment is given over a longer period. This protective effect might be mediated through stabilisation of bronchial responsiveness as observed during the present study. However, considering the potential for inhaled steroids to cause side effects, the natural tendency for recurrent wheezing in infancy to resolve and the likelihood that any potential benefit is marginal, we do not recommend the routine use of inhaled steroids in recurrently wheezing infants under the age of 18 months. However, treatment might be justified in those wheezy infants who continue to have severe recurent symptoms or reduced pulmonary function without spontaneous improvement.
